WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) announced clinical results presented today at the American Diabetes Association 68th Scientific Sessions of its Phase IIa trial of INCB13739, an orally bioavailable inhibitor of the 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) enzyme. These results showed that 28 days of treatment with INCB13739 significantly improved hepatic insulin sensitivity and decreased plasma LDL- and total-cholesterol levels in patients with type 2 diabetes. Results from this double-blind, placebo-controlled trial in 31 subjects diagnosed with type 2 diabetes were presented during an oral session entitled, “New and Novel Treatments for Diabetic Complications” by Meredith Hawkins, M.D., Department of Medicine, Division of Endocrinology, Albert Einstein College of Medicine and Principal Investigator for the trial.
